Eytan M. Stein, MD
The last few years have brought an explosion of new treatment options in the acute myeloid leukemia (AML) landscape, said Eytan M. Stein, MD, along with the need to molecularly monitor these patients and determine how to best sequence these agents.
, Stein sheds light on the current treatment landscape of AML, underscores the importance of molecular monitoring, and highlights where the field is headed.
OncLive®: What are some recent advances that have been made in the treatment of patients with AML?
: Our treatment options, up until very recently, were really quite limited. Patients could either receive induction chemotherapy with daunorubicin and cytarabine or get HMAs—that’s in the newly diagnosed setting. What has happened over the past few years is that there has been an explosion of new treatments for [patients with] AML.
... to read the full story